Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 16/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700718 | 0.88 | DHFR (0.61) | DHFRADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL6703945 | 0.87 | DHFR (0.74) | DHFR | |
| SCHEMBL6699847 | 0.81 | DHFR (0.52) | DHFR | |
| SCHEMBL20804429 | 0.79 | DHFR (1.00) | DHFR | |
| SCHEMBL6701226 | 0.78 | DHFR (0.73) | DHFR | |
| SCHEMBL22015905 | 0.77 | HPGD (0.65) | HSP90AA1METAP1 | |
| SCHEMBL20188098 | 0.77 | HPGD (0.65) | HSP90AA1METAP1 | |
| SCHEMBL6701191 | 0.77 | DHFR (0.72) | DHFR | |
| SCHEMBL6701864 | 0.75 | DHFR (0.59) | DHFR | |
| SCHEMBL10647855 | 0.75 | DHFR (0.56) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | claimed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0103464-B1 | DIAMINOPYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | claimed |
| US-4532240-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | claimed |
| EP-0103464-A2 | Diaminopyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0103464-B1 | DIAMINOPYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | disclosed |
| US-4532240-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0103464-A2 | Diaminopyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | ABCB1, ABCC1, DPYD | DHFR 81/4885ADORA3 2771/4885ADORA2A 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.